ClinicalTrials.Veeva

Menu

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France (Pro-TOCa)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Completed

Conditions

Ovarian Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT05204342
RECHMPL21_0742

Details and patient eligibility

About

Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.

Enrollment

22,500 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    • Diagnosic of Ovarian or Tubal Cancer C56 et C570
  • +/-
  • Carcinose péritonéale C786
  • Tumueur maligne secondaire de la plèvre C782,
  • Tumueur maligne secondaire des ganglions C770 à C779,
  • Tumueur maligne secondaire du foie C787,
  • Tumueur maligne secondaire du péritoine C786

Exclusion criteria

  • autres causes de :
  • Carcinose péritonéale C786
  • Tumueur maligne secondaire de la plèvre C782,
  • Tumueur maligne secondaire des ganglions C770 à C779,
  • Tumueur maligne secondaire du foie C787,
  • Tumueur maligne secondaire du péritoine C786

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems